Andera Partners Co-Leads $160 Million Series A for Alveus' Obesity Therapies

Andera Partners, a European private equity firm, announced its role in co-leading a $160 million Series A round for Alveus Therapeutics. This funding focuses on advancing Alveus' innovative therapies for obesity and metabolic diseases. The round sees participation from major investors including New Rhein Healthcare Investors, Omega Funds, and Sanofi Capital.

The funding will propel the Phase 2 development of ALV-100, Alveus' lead program promising significant weight loss maintenance. Additionally, funds will support the IND filing of ALV-200, targeting amylin receptors for enhanced efficacy and tolerability. Alveus, led by a seasoned management team, aims to innovate sustainable treatments for global healthcare challenges.

Jan Van den Bossche of Andera Partners remarks on their confidence in Alveus' potential to set new care standards. With operations in the US and Denmark, Alveus exhibits a strong global stance in metabolic disease innovation.